Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 26, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 840,000 Ordinary Shares of 25 pence each.
- Purchase Date: June 26, 2013.
- Price Range: Highest price paid was 1,625.5 pence per share; lowest price paid was 1,585.5 pence per share.
- Treasury Holdings (Settled): 514,189,512 shares (9.47% of total issued share capital).
- Treasury Holdings (Including Unsettled): 517,879,512 shares (10.53% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,915,987,959 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 840,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.53% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,915,987,959) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current Treasury share count (514,189,512 settled) against the company's total issued share capital.
- Note that the 10.53% Treasury holding figure includes shares purchased but not yet settled.